Validation of Serum Creatinine Dosage and Renal Clearance

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00323128

Enrollment

Registered

2006-05-09

Start date

2006-05-31

Completion date

2010-12-31

Last updated

2011-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure

Brief summary

This study has an open study design. The GFR will be measured using the renal clearance of inulin (Inutest) in volunteers with different stage of renal disease or without renal disease. A blood sample will be obtained for measuring serum creatinine in different laboratories.

Detailed description

In this study we will investigate the correlation between the GFR as measured by inulin clearance (golden standard) and the estimated GFR as measured by laboratories which used different serum creatinine assays in patients without renal disease and in patients with different stage of kidney failure.

Interventions

PROCEDURECalculation of inuline clearance

Calculation of inuline clearance.

PROCEDUREMeasuring serum creatinine

Measuring serum creatinine.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Normal weight as defined by a Body Mass Index of 18 to 30 kg/m2. * Subject is competent and willing to sign informed consent form after being given all the detailed information about the study. Informed consent form signed voluntarily. * The subjects must be in stable clinical condition, with stable serum creatinin at least for 6 months. * Persons with different stage of chronic renal disease and without kidney disease (living donors) who need an evaluation of the GFR or Admitted volunteers who easily obtain urine samples.

Exclusion criteria

* Transplant patients * Medication that will influence the serumcreatinine. * Morbid obesity * Pregnant, lactating females or females with childbearing potential without adequate contraception (use of oral contraceptives, IUD or condoms with spermicide). * History of allergy or hypersensitivity to inulin * Donation of blood in the 60 days preceding the first visit. * Liver disease, heart failure, nephrotic syndrome. * Patients in critically ill conditions. * Malnutrition * Postrenal kidney failure

Design outcomes

Primary

Measure	Time frame
Glomerular filtration ratio	At time T0
Serum creatinine	At time T0

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026